Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice.
about
Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patientsAutoantibodies to Potassium Channel KIR4.1 in Multiple SclerosisConnexin 43 astrocytopathy linked to rapidly progressive multiple sclerosis and neuromyelitis opticaClinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumabAquaporin 4 and neuromyelitis opticaThe Immunology of Neuromyelitis Optica-Current Knowledge, Clinical Implications, Controversies and Future PerspectivesHypersensitivity Responses in the Central Nervous SystemAntibodies as Mediators of Brain PathologyDevelopment, maintenance and disruption of the blood-brain barrierChallenges and opportunities in designing clinical trials for neuromyelitis opticaImmunology of neuromyelitis optica: a T cell-B cell collaborationMolecular pathogenesis of neuromyelitis opticaImmunology of neuromyelitis optica during pregnancyAntigen Presentation, Autoantigens, and Immune Regulation in Multiple Sclerosis and Other Autoimmune DiseasesTreatment of neuromyelitis optica: state-of-the-art and emerging therapiesPotassium channel KIR4.1 as an immune target in multiple sclerosisThe spectrum of MOG autoantibody-associated demyelinating diseasesCurrent concept of neuromyelitis optica (NMO) and NMO spectrum disorders.Optic neuritis in neuromyelitis optica.Neuromyelitis optica: clinical features, immunopathogenesis and treatment.Transient hyperckemia in the setting of neuromyelitis optica (NMO).Myelin-specific multiple sclerosis antibodies cause complement-dependent oligodendrocyte loss and demyelination.Aquaporin-4 autoantibodies increase vasogenic edema formation and infarct size in a rat stroke modelNeuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies: a decade later.Elevated C-X-C motif ligand 13 and B-cell-activating factor levels in neuromyelitis optica during remissionExpression of chemokine receptors on peripheral blood lymphocytes in multiple sclerosis and neuromyelitis optica.Immunodominant T cell determinants of aquaporin-4, the autoantigen associated with neuromyelitis optica.Experimental models of neuromyelitis optica.Aquaporins: important but elusive drug targets.Functional characterization of aquaporin-4 specific T cells: towards a model for neuromyelitis opticaAquaporin-4: orthogonal array assembly, CNS functions, and role in neuromyelitis optica.Identification of peptide targets in neuromyelitis optica.Seroprevalence and specificity of NMO-IgG (anti-aquaporin 4 antibodies) in patients with neuropsychiatric systemic lupus erythematosus.Intravenous neuromyelitis optica autoantibody in mice targets aquaporin-4 in peripheral organs and area postremaPotential therapeutic benefit of C1-esterase inhibitor in neuromyelitis optica evaluated in vitro and in an experimental rat modelSmall-molecule inhibitors of NMO-IgG binding to aquaporin-4 reduce astrocyte cytotoxicity in neuromyelitis optica.Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: frequency, origin, and diagnostic relevanceNeuromyelitis optica IgG causes placental inflammation and fetal death.Longitudinally extensive NMO spinal cord pathology produced by passive transfer of NMO-IgG in mice lacking complement inhibitor CD59.Cerebrospinal fluid aquaporin-4 antibody levels in neuromyelitis optica attacks.
P2860
Q21093230-D2A5EDAA-947B-429B-BBCF-EEE02B30FB80Q21129427-77684988-995A-48FD-AA60-6F132B12B6F2Q21132530-B9953338-B6D3-4714-A1DD-C0B8DB6D391AQ24598109-0E42003B-914C-4D20-B635-B092B0F600A3Q24613666-78D243B5-4ECA-4C63-BB3D-6071A9E6B190Q26767391-DAF0042B-B623-4518-A408-AF8D8C3AA56FQ26779177-BE042C2D-D77C-43D3-9F02-86CCE0803EFBQ26780374-709F0F05-7C39-4B87-B19E-31EF8C5EB182Q26829668-86E4D72E-2B85-4062-A210-3398824B2FA1Q26999708-9F058477-412D-4C09-A22A-4CCE63700B80Q27016045-2C1DFD3F-222F-4C0A-90C1-024AE4E33728Q27021535-A49F0094-6521-4C1C-B956-B846A2BD9968Q28078470-F26CBE07-204F-4553-A8F5-58B8AC1EDF62Q28080791-2B063DC8-A18D-4532-ADE9-C544A8AC8303Q28245749-FEED2E3C-101A-4B89-9938-D7414EF91FF7Q28270799-48D293B2-E8A2-4C7C-B3E4-BC16EE839DB4Q28293355-3FDE0383-63B6-4620-9B3A-08039B0947DEQ30577078-30271AB9-44FA-4612-9ABC-D66372778B24Q30610471-6207961D-E4C4-43BD-9558-B149D69076EFQ30785267-C51B9A34-09C2-4AB2-912A-8F80D3691912Q30826839-2B924461-7398-4795-9B05-2455A95950C4Q30842875-4BCF9042-C51A-4E34-B21F-AC70A26B4B6EQ30953714-FCA6FD32-66FA-49AE-9713-C3C969C39962Q30975717-6E15DB83-D7C1-436E-B5D2-4BF5A4750623Q33562130-F8453CB7-E57A-4753-9864-B5425F9ED859Q33743686-DE35E8B3-10A5-4BED-A7E6-2C2D398D94A8Q33769028-F0092830-A704-4BAF-B15E-C7CB53DD7BD9Q33785380-6F5E9260-7689-474D-9FAA-603A52D786E1Q33792739-41B30C40-FBE2-4723-9E02-1CE2121A4C00Q33802616-77D9D30C-8984-4A09-AF0F-932139565B64Q33892339-C7C917C0-C449-46D0-885C-D803E0947EBAQ33914842-78ABBD11-FE85-4C18-ADF4-69A9BAB8522DQ34061733-D3B4865C-4FBA-4302-B2DE-AEC1C7F180ACQ34072723-20D86726-3E5C-48CF-91C0-A01B48B870A4Q34142474-3034210D-163B-404E-BA50-ED5BC8BEE01DQ34154265-140FE6B7-6A0B-4FC8-8BE5-D69E20813798Q34154277-3F636C21-783F-4A1A-A2CB-461DF3A834BFQ34168084-E78AA154-3216-4C04-99BD-1A4DAFD41BDEQ34173376-8FE3C602-CAE8-4F81-A2E8-936CC05C05FBQ34235490-E44832EB-BF3F-45C4-AB6B-EEEF6EA7CD88
P2860
Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Intra-cerebral injection of ne ...... elitis optica lesions in mice.
@ast
Intra-cerebral injection of ne ...... elitis optica lesions in mice.
@en
type
label
Intra-cerebral injection of ne ...... elitis optica lesions in mice.
@ast
Intra-cerebral injection of ne ...... elitis optica lesions in mice.
@en
prefLabel
Intra-cerebral injection of ne ...... elitis optica lesions in mice.
@ast
Intra-cerebral injection of ne ...... elitis optica lesions in mice.
@en
P2093
P2860
P50
P356
P1433
P1476
Intra-cerebral injection of ne ...... yelitis optica lesions in mice
@en
P2093
A S Verkman
Angela Vincent
B Anthony Bell
P2860
P304
P356
10.1093/BRAIN/AWP309
P407
P577
2010-01-04T00:00:00Z